These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 1976361

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. T-cell depletion versus methotrexate as GvHD-prophylaxis in allogeneic bone marrow transplantation for leukaemia.
    Wiesneth M, Hertenstein B, Bunjes D, Schmeiser T, Arnold R, Heimpel H, Heit W.
    Eur J Haematol; 1988 Sep; 41(3):243-9. PubMed ID: 3053241
    [Abstract] [Full Text] [Related]

  • 3. Selective depletion of CD8 positive T-lymphocytes for prevention of graft-versus-host disease following allogeneic bone marrow transplantation.
    Champlin R, Gajewski J, Feig S, Giorgi J, Lyddane N, Lee K, Schmidt I, Winston D, Ho W, Reichert T.
    Transplant Proc; 1989 Feb; 21(1 Pt 3):2947-8. PubMed ID: 2495694
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. T cell depletion in bone marrow transplantation for leukemia: current results and future directions.
    Butturini A, Gale RP.
    Bone Marrow Transplant; 1988 May; 3(3):185-92. PubMed ID: 3048485
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
    Koehler M, Hurwitz CA, Krance RA, Coustan-Smith E, Williams LL, Santana V, Ribeiro RC, Brenner MK, Heslop HE.
    Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
    [Abstract] [Full Text] [Related]

  • 8. Immunohematological aspects of total body irradiation and bone marrow transplantation for the treatment of leukemia.
    van Bekkum DW, Hagenbeek A.
    Radiother Oncol; 1990 May; 18 Suppl 1():30-6. PubMed ID: 2247647
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.
    Mitsuyasu RT, Champlin RE, Gale RP, Ho WG, Lenarsky C, Winston D, Selch M, Elashoff R, Giorgi JV, Wells J.
    Ann Intern Med; 1986 Jul; 105(1):20-6. PubMed ID: 3521427
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors.
    Ash RC, Casper JT, Chitambar CR, Hansen R, Bunin N, Truitt RL, Lawton C, Murray K, Hunter J, Baxter-Lowe LA.
    N Engl J Med; 1990 Feb 22; 322(8):485-94. PubMed ID: 2300120
    [Abstract] [Full Text] [Related]

  • 15. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
    Filipovich AH, Vallera DA, Youle RJ, Haake R, Blazar BR, Arthur D, Neville DM, Ramsay NK, McGlave P, Kersey JH.
    Transplantation; 1987 Jul 22; 44(1):62-9. PubMed ID: 3299923
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A.
    Pediatrics; 1996 Sep 22; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E, Nagler A, Or R, Kapelushnik J, Slavin S.
    Clin Transpl; 1996 Sep 22; ():281-90. PubMed ID: 9286578
    [Abstract] [Full Text] [Related]

  • 20. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
    Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z.
    Br J Haematol; 1995 Mar 22; 89(3):506-15. PubMed ID: 7734348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.